Re: Farmas USA
RDUS
El cambio de CEO parece que responde directamente a la denegación de AMGN. Yo me iba a salir para esperar a la news de AMGN por si las moscas esta semana, pero, mira, por una vez me pilla dentro para bien. La denegación es todo un espaldarazo para RDUS, peero con eso y la nueva designación yo creo las posibilidades de buyout se reducen. A ver cómo se mueve git, pero quizá sea día de salir y esperarla más abajo.
FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO
After missing a key secondary endpoint for its big osteoporosis drug romosozumab last fall and then running into a disturbing safety issue two months ago, Amgen $AMGN said Sunday that the FDA has handed the big biotech a rejection on its marketing application, a widely anticipated setback for the drug developer that will give rival Radius a shot at establishing a big lead in what had once been thought of as a horse race. And within hours of the CRL news from Amgen, Radius put out the word that it is making a change at the helm, with longtime CEO Bob Ward out and Novo US president Jesper Høiland stepping in to orchestrate the campaign for Radius’ first market launch.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
